Phase 2
Development Phase
2
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
Target Indication
Diffuse Large B Cell Lymphoma
Clinical Trial
Last updated: 12/4/2025
Minjuvi
Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).
